Tagged with Strategy

Saudi Arabia Aymen Tamer, chairman and managing partner of historic Saudi healthcare firm Tamer Group, outlines how, informed by Saudi’s Vision 2030, the company is adapting to better meet the needs of the rapidly evolving domestic pharma market. Tamer also touches on the challenges of succession planning, why a deep and long-term…

Turkey Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both markets with a track record of six decades. In addition, Drechsel explains how the German company has moved from fifth…

Saudi Arabia Mohamed Fawzy highlights how Pfizer’s work in Saudi Arabia dovetails with the country’s ambitious ‘Vision 2030’ transformation strategy, the Saudi market’s increasing relevance to the company, and how Pfizer is working for the benefit of the Saudi people on COVID-19 vaccine access and beyond.   In simple terms, Vision 2030…

Turkey Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across MEA. Moreover, he comments on the future of antibiotics as the scientific community warns about antimicrobial resistance, the pandemic’s impact…

Turkey The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses the persisting issues within the country’s pricing and reimbursement system and why localization policies have been a net gain for…

China MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its strategically important China business. van Acker takes the helm against the backdrop of change at MSD, with a new global CEO and the abandonment of the company’s COVID-19 vaccine projects.…

Saudi Arabia Ashraf Daoud, General Manager for AbbVie in Saudi Arabia, highlights how the affiliate has harnessed Allergan’s portfolio to become a top five company in the market with the objective of becoming the biopharma leader by 2022. In addition, Daoud discusses the impact that an internal Saudization strategy has had, the…

Turkey Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles in Germany, Belgium, France and the US. She explains how Janssen Turkey’s vision “We are here for the better” is…

Indonesia With a market value of USD 5.2 billion, Kalbe Farma has consolidated into Indonesia’s undisputed national pharma champion and has established a footprint in many ASEAN countries as well as in Africa. Today, the largest publicly listed pharmaceutical company in Southeast Asia is aiming to seize on their COVID-19-related partnership…

Denmark On April 16, the Danish government unveiled, to great anticipation and fanfare, a brand-new National Life Science Strategy which seeks to chart the course for the next three years of an industry sector that has become increasingly influential for the country’s economy. Indeed, Denmark’s healthcare and life sciences segment now…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…

Saudi Arabia Lilly Saudi Arabia’s Dimitri Livadas shares some of the misconceptions he had before moving to the Kingdom a couple of years ago, highlights the evolution of the Saudi healthcare system with its current focus on digital health, the big opportunities for the Indiana-based company’s diabetes portfolio at a moment when…